Generic Semaglutide Could Cost Just $15 Monthly Worldwide

Global Pricing Projections

International health publications report that millions of patients worldwide will soon gain access to Ozempic and Wegovy alternatives at dramatically reduced prices. The $15 monthly price point represents a significant reduction from current brand-name costs, which typically range from $200 to $400 monthly in Canada.

The $3 per dose calculation suggests manufacturers can produce semaglutide at substantially lower costs than current brand pricing indicates. This aligns with previous manufacturing cost analyses showing the active ingredient can be produced for under $5 monthly.

Canadian Market Context

Canada remains the only major market where Novo Nordisk's semaglutide patent has expired, with the exclusivity period ending January 4, 2026. Health Canada is currently reviewing nine generic applications through its generic semaglutide tracker system.

Canadian pharmacies including Shoppers Drug Mart, Costco, and Walmart are expected to stock generic versions once Health Canada approvals are granted. The regulatory body has established a 180-day review timeline for the pending applications.

Manufacturing Companies Involved

Multiple pharmaceutical companies are positioning to enter the Canadian market with generic semaglutide formulations:

• Aspen Pharmacare targeting third-quarter 2026 launch
• Vimy Pharma preparing Canadian-manufactured versions
• Sandoz, Apotex, and Teva among major generic manufacturers
• Taro Pharmaceuticals and other established players

Current Brand Pricing in Canada

Brand-name semaglutide medications currently cost Canadian patients:

• Ozempic 0.5mg/1mg pens: $200-250 monthly
• Wegovy 2.4mg pens: $300-350 monthly
• Rybelsus oral tablets: $250-300 monthly

The projected $15 monthly generic price would represent savings of approximately 90-95% compared to current brand costs.

Insurance Coverage Considerations

Provincial health plans and private insurers are monitoring generic approvals before establishing coverage policies. The insurance coverage checker shows varying current coverage levels across Canadian jurisdictions.

Employer drug plans, which currently face significant budget pressures from brand-name GLP-1 medications, may expand coverage once generic alternatives become available at reduced pricing.

Market Competition Effects

Novo Nordisk has acknowledged that generic competition will impact sales in Canada. The company recently reduced Wegovy cash prices to $349 monthly, potentially in preparation for generic competition.

Eli Lilly's Mounjaro remains under patent protection until 2031, giving the tirzepatide manufacturer several additional years before facing generic alternatives.

Regulatory Timeline

Health Canada's review process for the nine pending generic applications continues under the established 180-day timeline. Approvals are anticipated throughout 2026, with the first generic launches possible by mid-year.

The regulatory body has not indicated any manufacturing quality concerns with the submitted applications, suggesting standard review procedures are proceeding.